1-5 of 5
Jason D. Morrow
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non–Small Cell Lung Cancer

Robert Mutter, Bo Lu, David P. Carbone, Ildiko Csiki, Luigi Moretti, David H. Johnson, Jason D. Morrow, Alan B. Sandler, Yu Shyr, Fei Ye, Hak Choy
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (6): 2158–2165.
https://doi.org/10.1158/1078-0432.CCR-08-0629
Published: 16 March 2009
View article titled, A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non–Small Cell Lung Cancer
Open the PDF for A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non–Small Cell Lung Cancer in another window
Journal Articles

A Phase I Trial to Determine the Optimal Biological Dose of Celecoxib when Combined with Erlotinib in Advanced Non–Small Cell Lung Cancer

Karen L. Reckamp, Kostyantyn Krysan, Jason D. Morrow, Ginger L. Milne, Robert A. Newman, Christopher Tucker, Robert M. Elashoff, Steven M. Dubinett, Robert A. Figlin
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (11): 3381–3388.
https://doi.org/10.1158/1078-0432.CCR-06-0112
Published: 01 June 2006
View article titled, A Phase I Trial to Determine the Optimal Biological Dose of Celecoxib when Combined with Erlotinib in Advanced Non–Small Cell Lung Cancer
Open the PDF for A Phase I Trial to Determine the Optimal Biological Dose of Celecoxib when Combined with Erlotinib in Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel

Ildiko Csiki, Jason D. Morrow, Alan Sandler, Yu Shyr, John Oates, Myles K. Williams, Thao Dang, David P. Carbone, David H. Johnson
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6634–6640.
https://doi.org/10.1158/1078-0432.CCR-05-0436
Published: 15 September 2005
View article titled, Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel
Open the PDF for Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel in another window
Journal Articles

Levels of Prostaglandin E Metabolite, the Major Urinary Metabolite of Prostaglandin E2, Are Increased in Smokers

Neil D. Gross, Jay O. Boyle, Jason D. Morrow, Myles K. Williams, Chaya S. Moskowitz, Kotha Subbaramaiah, Andrew J. Dannenberg, Anna J. Duffield-Lillico
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (16): 6087–6093.
https://doi.org/10.1158/1078-0432.CCR-05-0733
Published: 22 August 2005
View article titled, Levels of Prostaglandin E Metabolite, the Major Urinary Metabolite of Prostaglandin E<sub>2</sub>, Are Increased in Smokers
Open the PDF for Levels of Prostaglandin E Metabolite, the Major Urinary Metabolite of Prostaglandin E<sub>2</sub>, Are Increased in Smokers in another window
Journal Articles

Evaluation of 5-Aminosalicylic Acid (5-ASA) for Cancer Chemoprevention: Lack of Efficacy against Nascent Adenomatous Polyps in the ApcMin Mouse

Steve R. Ritland, Jonathan A. Leighton, Rhoda Elison Hirsch, Jason D. Morrow, Amy L. Weaver, Sandra J. Gendler
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (4): 855–863.
Published: 01 April 1999
View article titled, Evaluation of 5-Aminosalicylic Acid (5-ASA) for Cancer Chemoprevention: Lack of Efficacy against Nascent Adenomatous Polyps in the Apc<sup>Min</sup> Mouse
Open the PDF for Evaluation of 5-Aminosalicylic Acid (5-ASA) for Cancer Chemoprevention: Lack of Efficacy against Nascent Adenomatous Polyps in the Apc<sup>Min</sup> Mouse in another window